Peer-Reviewed Publication
Expert Opin Drug Saf2023;22(7):541-548.January 1, 2023Review
Will the future of pharmacovigilance be more automated?
Francesco Salvo1,2, Joelle Micallef3, Amir Lahouegue4, Laurent Chouchana5, Louis Létinier1,2,6, Jean-Luc Faillie7, Antoine Pariente1,2
1University of Bordeaux, Inserm, BPH, Team AHeaD, Bordeaux, France.
2CHU de Bordeaux, Service de Pharmacologie Medicale, Bordeaux, France.
3Pharmacovigilance Centre, Department of Clinical Pharmacology and Pharmacovigilance, University of Aix Marseille, INSERM UMR 1106 Institut de Neurosciences des Systèmes, Marseille, France.
4Department of Pharmacovigilance and Medical Information, Astrazeneca, Courbevoie, France.
5Regional Center of Pharmacovigilance, Pharmacology Department, Cochin Port Royal University Hospital, Paris, France.
6Synapse Medicine, Bordeaux, France.
7Inserm, Departement de Pharmacologie Medicale Et Toxicologie, Centre Regional de PV, Institut Desbrest D'epidemiologie Et de Sante Publique, CHU de Montpellier, Universite Montpellier, Montpellier, France.
Abstract
INTRODUCTION: Artificial intelligence (AI) based tools offer new opportunities for pharmacovigilance (PV) activities. Nevertheless, their contribution to PV needs to be tailored to preserve and strengthen medical and pharmacological expertise in drug safety.
AREAS COVERED: This work aims to describe PV tasks in which the contribution of AI and intelligent automation (IA) tools is required, in the…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans